Europe Obsessive-Compulsive Disorder (OCD) Drugs Market, By Severity (Mild to Moderate, Moderate to Severe), By Sub-Type (Contamination Obsessions with Washing/Cleaning Compulsion, Harm Obsessions With Checking Compulsions, Obsessions Without Visible Compulsions, Symmetry Obsessions with ordering, arranging and counting compulsions, hoarding, others), By Drugs (Antidepressants, Antipsychotics, NMDA Blocker, Others), By Route of Administration (Oral, Parenteral), By Population type (Pediatrics, Adults), By End User (Hospitals, specialty Clinics, Home healthcare, others), By Distribution Channel (Hospital pharmacy, Retail Pharmacy, Online Pharmacy, Others) By Country (France, U.K., Italy, Germany, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe).
Market Analysis and Insights: Europe Obsessive-Compulsive Disorder (OCD) Drugs Market
Europe Obsessive-Compulsive Disorder (OCD) Drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.2% in the forecast period of 2021 to 2028 and is expected to reach USD 274.47 million by 2028. Increasing generic approvals and awareness among people regarding the disorder and treatment products available are the major drivers which propelled the demand of the market in the forecast period.
Obsessive-compulsive disorder (OCD) refers to an anxiety disorder that is characterized by unreasonable and uncontrollable thoughts and fears leading an individual to perform repetitive behaviours. Obsessive-compulsive disorder is a disorder known to compel a person to get stuck on a particular thought or fear. The developments in the treatment, therapies and novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs is expected to provide various other opportunities in the OCD drugs market. However, patent expiry of the patented drugs and introduction of generic version of branded drugs are factors expected to restraint the market growth in the forecast period.
The OCD drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Obsessive-Compulsive Disorder (OCD) Drugs Market Scope and Market Size
Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Europe obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
- On the basis of subtype, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the Europe obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
- On the basis of drugs, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS) and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole and others. NMDA blocker is further segmented into ketamine, memantine and others. In 2021, the antidepressants segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
- On the basis of route of administration, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablet, capsules and solution. In 2021, the oral segment is dominating the Europe obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Europe obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Europe obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Europe obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Europe, U.K. is the dominant region due to rising cases of genetic inherited disorders and rising adoption of gene therapy.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user and distribution channel.
The countries covered in the OCD drugs market report are France, U.K., Italy, Germany, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.
Oral segment in Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of the developments in the treatment, therapies and novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs and improving healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players and rise in demand of OCD drugs are boosting the Market Growth of OCD drugs products.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and OCD Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies which are dealing in the Obsessive-Compulsive Disorder (OCD) drugs are H. LUNDBECK A/S, Apotex Inc., Teva Pharmaceutical industries Ltd. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Lannett, GlaxoSmithKline plc., Pfizer Inc., Mallinckrodt, Sebela Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., , Wockhardt, Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Abbott, Eli Lilly and Company, Viatria Inc., among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the OCD drugs market.
For instance,
- In January 2021, Lundbeck enters a new partnership with the Department of Neurosurgery (Afdeling for Hjerne- og Nervekirurgi) at Rigshospitalet in Copenhagen, which will provide new insights into how molecules enter the brain. The partnership gives researchers an opportunity to study fluids surrounding the brain to learn which compounds enter the brain and how they are distributed. The project is basic research, with a view to making the results widely available.
- In April 2021, Apotex inc. announced the initiation of voluntary type 1 recall of APO-AMITRIPTYLINE 10mg. The recall is initiated due to the one lot (PY1831) in which the acceptable intake limit of NDMA, as established by Health Canada, has been exceeded. This has somehow caused financial loss to the company.
- In March 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the OCD drugs market which also provides the benefit for organization to improve their offering for OCD drugs products. .
SKU-